Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07594145 · ClinicalTrials.gov registry record · Phase 2
Precision T1D Platform - New Therapies for Cardio-Renal Complications
A Phase 2 study, sponsored by Oregon Health and Science University.
- Not yet
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
NCT07594145 is a Phase 2 study that has not yet begun recruiting, run by Oregon Health and Science University. The registered enrollment target is 57 participants.
The verdict
NCT07594145, a Phase 2 study, has not yet begun recruiting, sponsored by Oregon Health and Science University.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
Study Summary
Breakthrough T1D has awarded support for a joint University of Michigan-Oregon Health \& Science University Center of Excellence (CoE) to address cardio-renal complications in T1D. The overarching hypothesis of the CoE is that individuals with T1D have unique endophenotypes determining their progression towards cardio-renal end organ damage. Defining the underlying molecular programs in T1D endophenotypes provides the rationale for testing existing or new drug candidates in mechanistic trials targeting T1D cardio-renal complications by matching endophenotypes to targeted therapies.
Interventions
- DRUG Finerenone
- DRUG Sotagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2026-09-01 |
| Est. Completion | 2031-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07594145
The ClinicalTrials.gov registry entry for NCT07594145 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Finerenone is the first listed.
NCT07594145 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07594145 about?
NCT07594145 is a clinical study titled "Precision T1D Platform - New Therapies for Cardio-Renal Complications". Breakthrough T1D has awarded support for a joint University of Michigan-Oregon Health \& Science University Center of Excellence (CoE) to address cardio-renal complications in T1D. The overarching hypothesis of the CoE is that individuals with T1D have unique endophenotypes determining their progres...
What is the current status of trial NCT07594145?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2026-09-01. Estimated completion is 2031-12-31.
What interventions are being tested in trial NCT07594145?
The interventions under investigation include: Finerenone (DRUG), Sotagliflozin (DRUG).
Who is sponsoring clinical trial NCT07594145?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.